{
  "docId": "019de072-4b47-73db-b658-db74b88c61ed",
  "docSlug": "479ed371379fcba7e292c76acd5b0af7",
  "documentTitle": "BioNTech | Results Presentation Deck | 37 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 37,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4b47-73db-b658-db74b88c61ed/30",
  "deckHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed",
  "deckJsonHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed.json",
  "deckAnchorHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.63,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1 Ranges reflect current base case projections and do not include potential effects caused by or driven from additional collaborations or potential M&A transactions. 2 BioNTech Group estimated annual effective income tax rate decreased from 31.6% (FY 2021) to ~28% (FY 2022) due to decreasing average trade tax rates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e96eff25-d162-47c8-a7ac-7fd3c3ca7f97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.189
      },
      "kind": "table",
      "text": "COVID-19 Vaccine Revenues for FY 2022: € 13 – 17 bn; R&D expenses: € 1,400 - 1,500 m; SG&A expenses: € 450 - 550 m; Capital expenditure: € 450 - 550 m; BioNTech Group estimated annual effective income tax rate: ~28%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4240392-1a53-4652-839e-f4e6bf161568",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.39,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "2022 Financial Year Guidance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20ede681-55fc-4cb7-9497-fa5597f6861e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}